Table 2 Model training and validation for the 24 included studies
First author and year | Target condition | Reference standard | Type of internal validation | External validation |
|---|---|---|---|---|
Zhou Z, 2021 | MCL | Histopathology | Five-fold cross validation | Yes |
McAvoy M, 2021 | PCNSL | Histopathology | NR | No |
Li D, 2020 | DLBCL | Histopathology | NR | No |
Miyoshi H, 2020 | DLBCL, FL | Histopathology or expert consensus | Five-fold cross-validation | No |
Park JE, 2020 | Lymphoma | Histopathology | NR | Yes |
Mohlman JS, 2020 | BL, DLBCL | Histopathology | Leave-one-out cross-validation | No |
Achi HE, 2019 | DLBCL, BL, SLL | Histopathology | NR | No |
Im H, 2018 | Lymphoma | Histopathology | Random split-sample validation | No |
Guan Q, 2019 | NHL | Histopathology | NR | No |
Guo R, 2021 | ENKTL | Histopathology | NR | No |
Xia W, 2021 | PCNSL | Histopathology | Five-fold cross validation | No |
Zhang Y, 2021 | PCNSL | Histopathology | NR | No |
Syrykh C, 2020 | FL | Histopathology | NR | Yes |
Wang H, 2020 | ENKTL | Histopathology | Ten-fold cross-validation | No |
Zhang J, 2020 | NHL | NR | Five-fold cross validation | No |
Wang Q, 2017 | ALL | Histopathology | Cross validation | No |
Schouten JPE, 2021 | ALL | Expert consensus | Tenfold cross-validation | No |
Nakagawa M, 2018 | PCNSL | Expert consensus | Ten-fold cross-validation | No |
Shafique S, 2018 | ALL | Expert consensus | NR | No |
Kong Z, 2019 | PCNSL | Histopathology | Five-fold cross validation | No |
Weisman AJ, 2020 | Lymphoma | Expert consensus | Five-fold cross validation | No |
Kim Y, 2018 | PCNSL | Histopathology | Ten-fold cross-validation | Yes |
Styczeń M, 2012 | Splenic and gastric marginal zone lymphoma | Histopathology | NR | No |
Guo J, 2018 | OAL | Histopathology | NR | No |
Azamossadat H, 2023 | B-ALL | Histopathology | NR | No |
Chava P, 2023 | DLBCL, HGL | Histopathology | NR | Yes |
Jermphiphut J, 2023 | PCNSL | Histopathology | NR | No |
Hikaru A, 2023 | DLBCL | Histopathology | Five-fold cross-validation | No |
Manjit K, 2023 | ALL | Histopathology | NR | No |
Noriaki H, 2023 | DLBCL, FL and RL | Histopathology | Five-fold cross-validation | Yes |